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Background: Maternal smoking during pregnancy is a major risk factor for adverse health outcomes. The main
objective of the study was to assess the impact of in utero tobacco exposure on DNA methylation in children born
at term with appropriate weight at birth.
Methods: Twenty mother-newborn dyads, after uncomplicated pregnancies, in the absence of perinatal illness were
included. All mothers were healthy with no cardiovascular risk factors, except for the associated risks among those
mothers who smoked. Umbilical cord blood and maternal peripheral venous blood were collected and an epigenome-
wide association study was performed using a 450 K epigenome-wide scan (Illumina Infinium HumanMethylation
450BeadChip) with adjustment to normalize the DNA methylation for data cell variability in whole blood.
Results: The maternal plasmatic cotinine levels ranged from 10.70-115.40 ng/ml in the exposed group to 0-0.59 ng/ml
in the non-exposed group. After adjusting for multiple comparisons in 427102 probes, statistically significant differences
for 31 CpG sites, associated to 25 genes were observed. There was a greater than expected proportion of statistically-
significant loci located in CpG islands (Fisher’s exact test, p = 0.029) and of those CpG islands, 90.3% exhibit higher
methylation levels in the exposed group. The most striking and significant CpG site, cg05727225, is located in the
chromosome 11p15.4, within the adrenomedullin gene.
Conclusions: In utero tobacco exposure, even in the absence of fetal growth restriction, may alter the epigenome,
contributing to global DNA hypomethylation. Therefore, DNA status can be used as a biomarker of prenatal insults.
Considering the possibility to reverse epigenetic modifications, a window of opportunity exists to change the
programmed chronic disease.
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Maternal smoking during pregnancy is a major risk
factor for adverse health outcomes in children. Recent
evidence suggests that it has consequences that are not
only immediate, such as low birth weight, but it also
leads to long-term risk for obesity, type 2 diabetes, ele-
vated blood pressure and neurobehavioral defects in
children [1-4]. Despite public health warnings, in Spain
16% of pregnant women are smokers [4], implying that
a large number of offspring are at risk. Even though it* Correspondence: empar.lurbe@uv.es
1Pediatrics Department, Consorcio Hospital General, University of Valencia,
Valencia, Spain
2CIBER Fisiopatología Obesidad y Nutrición (CB06/03), Instituto de Salud
Carlos III, Madrid, Spain
Full list of author information is available at the end of the article
© 2015 Ivorra et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.is clear that there are adverse health consequences, the
mechanisms behind the relationship between in utero
tobacco exposure and its effects are not well understood.
Changes to DNA methylation can occur throughout
life, but much of the epigenome is established during
embryogenesis and early development of the fetus [5].
Epigenome changes that are mitotically stable and
heritable are also sensitive to environmental stimuli.
Then, the epigenetic process provides a window through
which, the genes that are involved in the lifelong effects of
in utero insults, can be identified [6]. DNA methylation in
different regions can have different effects. While in gene
promoter regions, overall those located in cytosine–
guanine dinucleotide (CpG) islands, reduce the genehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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crease the transcription [7].
Recent studies in human populations have demonstrated
that tobacco exposure may induce epigenetic alterations,
specifically by altering patterns of DNA methylation [8].
Although largely studied in adult smokers, few human
studies have examined epigenetic alterations in relation
to maternal smoking during pregnancy and reported it
to be associated with global methylation of leukocyte
DNA [9-11]. These studies have used global methylation
with a [3H]-methyl acceptance assay [9,10] or differential
methylation at CpG sites [11]. Maternal smoking during
pregnancy has also been associated with global and CpG-
site specific methylation in human placenta [11] as well as
in buccal cells from children [12].
The objective of the present study was to assess the
impact of in utero tobacco exposure on DNA methylation
in children born at term and appropriate for gestational
age. The epigenome-wide association study was performed
on umbilical cord blood, using a global methylation assay
and a 450 K epigenome-wide scan with the Houseman ad-
justment method [13] to normalize the DNA methylation
for data cell variability in whole blood. Cotinine levels in
umbilical cord blood were the markers of in utero tobacco
exposure.Methods
Study participants
Subjects were recruited from those born in the Hospital
General Universitario of Valencia, Spain between January
and December 2011. Mothers were invited to participate
at the time of their admission to the Hospital for delivery.
Exclusion criteria were missing information about the
pregnancy. Twenty newborns and their mothers fulfilled
the criteria of being of European origin, born at term
(gestational age ≥37 weeks), and appropriate for gesta-
tional age, defined as weight at birth between 10th and
90th percentile [14]. All subjects were born from un-
complicated pregnancies in the absence of perinatal ill-
ness, and gave informed parental consent to participate.
Additional inclusion criteria were the concordance be-
tween the questionnaire and the cotinine levels. Mothers
completed a questionnaire that included the details of
their smoking habits. Eligibility by exposed status was de-
termined through maternal self-report and confirmed by
blood cotinine levels. Subjects were included in the ex-
posed group from those who were daily smokers before
pregnancy and maintained the same habit throughout the
three trimesters. All mothers were healthy with no cardio-
vascular risk factors, except the associated risks among
those mothers who smoked. Additionally, subjects were
selected for the non-exposed group based on sex distribu-
tion and mothers’ age.In utero tobacco exposure was assessed by cotinine
determination in plasma from maternal peripheral blood
and in the infants’ umbilical cord blood. Umbilical cord
blood samples were obtained from the clamped umbilical
cord immediately after delivery. Samples from the mothers
were drawn 24 h after delivery. The samples and collected
data were stored according to the directives dictated
by the law of Biomedical Investigation of 2007 (Law
14/2007). The study was approved by the review board
of the Hospital General Universitario de Valencia and
was carried out in accordance with the Declaration of
Helsinki. Plasma and DNA from umbilical cords of the
newborns and from peripheral veins from the mothers,
as well as the collected data, were stored according to
the directives dictated by the law of Biomedical Inves-
tigation of 2007 (Law 14/2007) and all applicable rules.
Tobacco exposure was measured using an immunoassay
for cotinine (Salimetrics, SPK 1-2002-5) according to the
manufacturer’s recommendations. The minimum concen-
tration that can be distinguished is 0.05 ng/ml. Newborn
groups were created according to cotinine levels in umbil-
ical cord; higher than 10 ng/ml was qualified as exposed
to in utero tobacco and lower than 1 ng/ml was consid-
ered as non-exposed to in utero tobacco.Sample collection, DNA extraction, quantification and
quality check
Umbilical cord blood and maternal peripheral venous
blood were collected in EDTA-tubes, centrifuged to yield
plasma, stored at -80°C and thawed before use. Genomic
DNA was extracted from venous umbilical cord blood
with the RealPure kit (REALPURE, REAL, DURVIZ, Ref:
RBMEG01) and was quantified with the Nanodrop-2000C
Spectrophotometer. A DNA quality check was performed
with Quant-iT PicoGreen dsDNA reagent.Global DNA methylation assay
The global DNA methylation levels in umbilical cord
blood samples were obtained with an ELISA commercial
kit (5-mC DNA ELISA Kit, Zymo Research, D5325).
Two hundred nanograms (ng) of DNA were diluted with
250 μl of 5-mC Coating buffer lysis and incubated at 98°C
for 5 minutes. After denaturation, DNA were transferred
to the plate and incubated at 37°C for one hour. The
samples were incubated with capture and detection
antibodies and absorbance was read at 450 nanometers.
Quantification of global DNA methylation was obtained
from calculating the amount of methylated cytosines in
the sample (5 mC) relative to global cytidine (5 mC + dC)
in a standard curve following positive control that had
been previously methylated. All samples were analyzed in
duplicate.
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Genomic DNA (one μg) from each subject was treated
with sodium bisulfite using the EZ DNA Methylation kit
(ZYMO RESEARCH CORP, Irvine, CA, USA) according
to the manufacturer’s recommendations. The incubation
profile was 16 cycles at 95°C for 30 s, 50°C for 60 min
and a final holding step at 4°C (incubation conditions rec-
ommended when using the Illumina Infinium Methylation
Assay). The methylation assay was performed on 4 μl
of converted bisulfite DNA using the Illumina Infinium
HumanMethylation 450BeadChip following the Infinium
HD Methylation Assay protocol.
For HumanMethylation 450 K array analysis, the sam-
ple was divided in 2 groups of 10 samples with the same
proportion of samples corresponding to the exposed and
non-exposed groups and samples were located in the chip
by random distribution, in order to avoid the batch or
localization effects. Methylation profiling of the samples was
carried out using Illumina Infinium HumanMethylation450
BeadChip Kit (Illumina). Instead of using Illumina's
GenomeStudio software, raw IDAT files were obtained
and further preprocessed using the R/Bioconductorminfi
package [minfi]. Red and green channel intensities were
obtained from the raw IDAT files. Detection p-values for
each probe were also computed and used in order to dis-
card those probes with low quality. A probe was discarded
if at least 2 of its detection p-values were over 0.01.
The normalization step used the SWAN method to
correct the differences that appeared due to the two dif-
ferent probe designs present in the Infinium Human-
Methylation450 [15]. A set containing both M
(methylated) and U (unmethylated) signals was obtained
as a result of these two normalization steps.
Probes contained in the set with the M and U signals
were annotated in a separate step. Probes where at least
two samples had detection p-values over 0.01 were fil-
tered out. Each probe was initially labelled with the in-
formation included in the Illumina Manifest file which
was directly related to the location-dependent properties
of the probe, including the chromosomal location of the
probe, percent GC and source genomic sequence for the
probe, among other fields. All the annotation data needed
for the posterior analyses was dynamically evaluated using
the rtracklayer package from R/Bioconductor [rtracklayer]
for accessing the UCSC Browser database [ucsc].
Nearest gene ID, symbol and the distance from the
probe to the nearest TSS were obtained from the TxDb.
Hsapiens.UCSC.hg19.knownGene [txdb] and BSgenome.
Hsapiens.UCSC.hg19 [bsgenome] packages from R/
Bioconductor. CpG Island status was evaluated with
respect to R. Irizarry's automatically-generated de-
scription of CpG Island regions, which is by default
included in the FDb.InfiniumMethylation.hg19 package
from R/Bioconductor. Shores were defined as 2 kb regionsflanking CpG Islands, and Shelves as 2 kb regions follow-
ing the respective upstream and downstream Shores.
From the M and U signals, both beta-values were gen-
erated (which are easier to interpret from a biological
point of view) and M-values (a transformation of beta
values to achieve homoscedasticity [mvalues]).
All CpG loci on X and Y chromosomes were excluded
from the analysis to avoid sex-specific methylation bias.
Probes that were found to be cohybridated with probes
in the sexual chromosomes [16] were also removed. The
information from the SNP137Common track from the
UCSC browser was used [17], in order to remove those
probes with an SNP located inside their 2 bp central
region.
Data analysis
Differences in global DNA methylation were sought by
using Student’s t-test for independent samples. A linear
model approach was performed to identify individual CpG
loci showing differential methylation values associated
with in utero tobacco exposure. Significant differentially
methylated probes were determined by the moderated
t-test implemented in the R/Bioconductor package "limma"
[18]. P-values were adjusted by controlling the FDR (using
the Benjamini-Hochberg method). Probes with adjusted
p-values under a 0.05 significance level were selected.
Samples were clustered according to their Euclidean Dis-
tance, and a complete linkage clustering method was used
for generating the dendrograms.
Methylation data was adjusted for white blood cell
heterogeneity using the method described in [13]. Since
unfractioned PBLs from whole blood was collected, the
methylation profile in PBLs represents the aggregate
methylation profile of a complex cellular mixture. Thus,
even small changes in percentage methylation may indicate
considerable differences in underlying cell populations. To
address this limitation, a novel statistical methodology, cre-
ated by Houseman and co-workers [13] was employed.
This method was used to quantify the proportion of total
variability in cord blood DNA methylation explained by
estimated immune cell composition between subjects.
In order to feed this method, the original Illumina 27 k
database of purified white blood cell subtypes was used,
included in the authors' original implementation of the
algorithm.
Adrenomedullin quantification
The adrenomedullin (ADM) concentration in plasma
from umbilical cord samples was determined using a
high sensitivity ELISA kit for human Adrenomedullin,
(Uscn Life Sicence, Cat. No. CEA220Hu), according to
the manufacturer’s protocol. All samples were analyzed
in duplicate. The minimum detectable dose of ADM is
4.77 pg/mL.
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The HumanMethylation450 BeadChip data sets from this
study have been submitted to the NCBI Gene Expression
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under
accession number GSE64316.
Results
General clinical and anthropometric characteristics of the
study population
The general characteristics of the newborns and their
mothers included in this study are in Table 1. Two groups
of newborns were considered, exposed (n = 10, five females)
and non-exposed (n = 10, five females) to in utero tobacco.
The maternal plasmatic cotinine levels ranged from 10.70-
115.40 ng/ml in the exposed group to 0-0.59 ng/ml in the
non-exposed group (see Table 1). In exposed and non-
exposed mothers no differences were observed in BMI
at the beginning of pregnancy (20.8 ± 4.4 vs 23.3 ± 5.1,
p = 0.26) and BPs (110/67 ± 7.3/6.9 vs 106/66 ± 6.8/5.9,
p = 0.21 and 0.61, respectively) as well as BP at the time
of labour (126/69 ± 4.6/4.2 vs 125/73 ± 5.8/5.2, p = 0.56
and 0.13, respectively). When the general characteris-
tics from the two groups were analyzed, no significant
differences were observed in maternal age, gestational
age, length, blood pressure and heart rate between ex-
posed and non-exposed newborns. However, birth
weight was significantly lower among exposed and non-
exposed newborns (3361 g ± 272 vs 3713g ± 147; p-value
= 0.0021) although none were qualified as small for gesta-
tional age, birth weight <10th percentile [14].Table 1 General characteristics of mother and newborns
grouped according to in utero tobacco exposure
Variable Exposed
(n = 10)
Non-exposed
(n = 10)
p-value
Maternal Characteristics
Maternal age (years) 31.3 ± 6.8 29.9 ± 7.4 0.681
Maternal Cotinine (ng/ml) 58.30 ± 34.23 0.05 ± 0.16 <0.001
Newborn Characteristics
Gestational age at delivery
(wk)
38.9 ± 1.45 38.9 ± 0.74 1.000
Sex (male/female) 5/5 5/5
Birth weight (g) 3361 ± 272.2 3713 ± 147.3 0.0021
Length (cm) 49.9 ± 1.47 49.5 ± 1.58 0.928
Systolic blood pressure
(mmHg)
74.43 ± 13.62 74.60 ± 13.72 0.979
Diastolic blood pressure
(mmHg)
47.73 ± 13.42 44.57 ± 12.69 0.594
Heart rate (bpm) 119.40 ± 11.74 119.43 ± 10.32 0.963
Umbilical cord blood cotinine
(ng/ml)
65.47 ± 36.71 0.115 ± 0.24 <0.001
The values are expressed as mean ± SD; p-value, statistical significance of the
differences among groups.Global DNA methylation
Global DNA methylation status in whole blood was
compared between the groups using a 5-methyl Cytosine
kit. A significantly lower global methylation was found
in the exposed group (see Figure 1A).
Epigenome-wide analysis by 450 K platform
Epigenome-wide DNA methylation profile was determined
using Illumina Human BeadsChips 450 K. This array en-
ables site-specific methylation status of 485577 CpG sites
across the human genome. It contains probes to detect
methylated and unmethylated sequences and data from
probes are used to calculate a β-value between 0 and 1
(equivalent to 0%-100% methylation). After quality control
(3457 probes were excluded), methylation data from
482120 CpG sites were available. The methylation ana-
lysis of 10916 probes located in X/Y chromosomes is
perfectly correlated with gender. After this verification,
all CpG loci on X and Y chromosomes were excluded
from the analysis to avoid sex-specific methylation bias.
Additionally, the CpG sites containing a common SNP
or co-hybridizing probes in sexual chromosomes were
removed to avoid sex-specific methylation bias and biases
related to genetic variability respectively. The final dataset
comprised methylation data for 427102 autosomal CpG
loci for analysis in 20 samples.
To identify individual CpG loci whose methylation sta-
tus was associated with prenatal tobacco exposure, the
differential locus-specific patterns were examined. After
adjusting for multiple comparisons using a FDR 0.05 in
427102 probes, statistically significant differences for 31
CpG sites, associated to 25 genes were observed (5 genes
present 2 sites with differential methylation and one of
the sites is located in an intergenic region). Table 2 dis-
plays all CpG sites with a significant differential methyla-
tion between exposed and non-exposed groups. A visual
representation of the genome-wide distribution of the
significant differentially-methylated CpG sites of exposed
vs. non-exposed is represented as Manhattan plot in
Figure 1B. We found a greater proportion of loci lo-
cated in CpG islands compared to those outside of these
regions (Fisher’s exact test, p = 0.029) (Figure 2). Those
methylation sites located in CpG islands showed higher
methylation levels (90.3% of the sites) in the exposed
group. Only 3 CpG sites were hypomethylated in the ex-
posed group.
The most striking and significant CpG site, cg05727225,
(adjusted p-value = 0.03282, fold change = 0.3474) is located
in the chromosome 11p15.4, within the ADM gene. Three
more CpG sites are located in the 11 chromosome:
cg24962978 associated to RPS25 gene, and cg03529555 and
cg01249134 loci associated to NAV2 gene. On chromo-
some 1, 4 CpG sites were found in which methylation is
increased in the exposed group associated to HIST3H2A,
Figure 1 Global DNA Methylation. A) Global DNA methylation index in cord blood DNA of 10 newborns exposed to in utero tobacco, and 10
newborns non-exposed to in utero tobacco (Box plots). B) Manhattan plot for methylation status in umbilical cord blood DNA from newborns
exposed or non-exposed to in utero tobacco. The vertical axis indicates (-log10 transformed) observed p-values and the horizontal threshold indicates
the significance level (p = 1x10−5).
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hypomethylated in HIST3H2BB gene in the exposed
group. Other genes in which methylation is statistically
significant between the study groups are FOXP4, ZNF827,
AIRE, GPATCH1, CASP7, MIR3656, TRAPPC4, DDAH2,
NDUFA4L2, LINC00669, C19orf47, PLD3, CELF6, RPL27,
AKIRIN1, FAM124A, HS3ST5, RSU1, ZBTB45, KCNJ3,
SPSB4 and PDE4D. Locations, p-values, rank and fold
changes are provided in Table 2.
Unsupervised clustering of samples using the methyla-
tion signals of the 31 differentially methylated CpG sites
revealed two main clusters: one cluster comprising the
exposed newborns and the other containing the non-
exposed newborns (Figure 3). Interestingly the samples
displaying higher differential methylation correspond to
the newborns that were more exposed to tobacco com-
pounds (N2, N4 and N13).
Adrenomedullin
Adrenomedullin in the cord blood of the exposed and
non-exposed groups was assessed and the mean levels
were 10.0 ± 2.2 and 10.2 ± 3.9 pg/mL respectively. Fur-
thermore there were no significant differences in ADM
values in the umbilical cord status between groups ad-
justed for birth weight. When the groups were divided
into those with lowest (n = 5 in each group) and highest
(n = 5 in each group) birth weights, in the 10 smaller
newborns of the exposed and non-exposed groups the
mean was 10.3 ± 2.7 and 7.6 ± 1.9 respectively (p = 0.72).
In the 10 larger newborns of the 2 groups the mean was
9.7 ± 1.8 and 12.6 ± 3.5, respectively (p = 0.58).
Discussion
The impact of in utero tobacco exposure on DNA methy-
lation is of great interest. Patterns of DNA methylation,
which have a role in switching genes on and off, aresubstantially established during embryogenesis and fetal
development. In this way, the findings of the present study
provide additional information on the issue. Inappropriate
for gestational age newborns, born at term, DNA global
methylation of umbilical cord blood was lower in those
exposed to in utero tobacco as compared to the non-
exposed. Moreover, using a 450 K epigenome-wide scan
and after adjusting by cell type composition and multiple
comparisons, 31 CpG sites with significant differences
in methylation between the exposed and non-exposed
groups were obtained. It was found for the first time,
that the striking and significant locus that is most dif-
ferentially methylated is designated to the ADM gene,
and is hypermethylated.
The present study has characteristics that need to be
considered. At term and appropriate for gestational age
newborns were included, avoiding the effect of intrauter-
ine growth restriction. Cotinine, the most sensitive bio-
marker to evaluate tobacco exposure [19], was measured
in maternal plasma samples and umbilical cord blood in
newborns. However, due to its short half-life in blood
during pregnancy, it reflects only recent maternal smoking.
Therefore questionnaires were employed to confirm that
the smoking habit was maintained prior to and throughout
the pregnancy.
The epigenetic-wide DNA profile of whole blood from
umbilical cord was assessed by using a 450 K Illumina
platform with the innovative Houseman methodology to
exclude potential confounders [13]. A previous study,
which used the Illumina 450 K platform [20] measured
DNA methylation in unfractionated PBLs with respect
to cell variability in whole blood samples representing the
methylation of a complex cellular mixture. The method
used in the present study normalizes the DNA methyla-
tion data with respect to cell variability in whole blood
samples [13]. This approach has already successfully
Table 2 Significantly differentiated methylated CpG sites of newborns exposed to inutero tobacco compared to
non-exposed
CpG Chromosome Gene Logfold change p-value Adjusted p-value Delta beta Rank CpG_location
cg05727225 11p15.4 ADM 0.3474 1.32xe-07 0.03282 0.0432 1 CpG island
cg00387170 6p21.1 FOXP4 0.4894 2.71xe-07 0.03282 0.0740 2 CpG island
cg13907959 1q42.13 HIST3H2A −0.4731 2.72xe-07 0.03282 −0.0409 3 CpG island
cg02738677 1q42.13 HIST3H2A 0.4894 5.56xe-07 0.0385 0.0685 4 Non-CGI
cg04402350 4q31.22 ZNF827 0.5450 3.07xe-07 0.0328 0.0676 5 CPG island
cg25783241 21q22.3 AIRE 0.2620 6.34xe-07 0.0385 0.0435 6 CPG island
cg04177517 19q13.11 GPATCH1 0.3278 8.06xe-07 0.0385 0.0778 7 CGI-Shore
cg12331332 10q25 CASP7 0.3305 9.07xe-07 0.0385 0.0390 8 CPG island
cg24962978 11q23.3 RPS25 0.5570 9.13xe-07 0.0385 0.0742 9 CPG island
cg15264752 6p21.3 DDAH2 0.4845 1.00xe-06 0.0385 0.0526 10 CPG island
cg23240961 12q13.3 NDUFA4L2 0.5615 1.06xe-06 0.0385 0.0666 11 CPG island
cg27561567 17q11-qter CLTC 0.2552 1.08xe-06 0.0385 0.0623 12 Non-CGI
cg08533403 19q13.2 PLD3 0.4951 1.31xe-06 0.0403 0.0750 13 CPG island
cg03621881 15q24 CELF6 0.4745 1.32xe-06 0.0403 0.0522 14 CPG island
cg12556991 17q21 RPL27 0.5845 1.55xe-06 0.0403 0.0528 15 CPG island
cg13549152 1p34.3 AKIRIN1 0.2472 1.57xe-06 0.0403 0.0494 16 CGI-Shore
cg10454248 13q14.3 FAM124A 0.5438 1.60xe-06 0.0403 0.0532 17 CPG island
cg09048334 17q21 RPL27 0.3934 1.98xe-06 0.0472 0.0919 18 CPG island
cg00093900 1q32.1 PPP1R15B 0.3873 2.39xe-06 0.0494 0.0363 19 CPG island
cg02192300 13q14.3 FAM124A 0.3810 2.63xe-06 0.0494 0.0446 20 CPG island
cg03529555 11p15.1 NAV2 −0.4831 2.72xe-06 0.0494 0.0642 21 Non-CGI
cg26547359 HS3ST5 −0.4682 2.89xe-06 0.0494 0.0524 22 CPG island
cg01249134 11p15.1 NAV2 0.3364 3.05xe-06 0.0494 0.0758 23 CGI-Shelf
cg07455406 RSU1 0.2540 3.08xe-06 0.0494 0.0624 24 CPG island
cg12271800 19q13.43 ZBTB45 0.4554 3.10xe-06 0.0494 0.0473 25 CPG island
cg25932748 2q24.1 KCNJ3 0.5870 3.18xe-06 0.0494 0.0666 26 CGI-Shore
cg17423711 1q24.2 POU2F1 0.3053 3.24xe-06 0.0494 0.0260 27 CPG island
cg23332582 3q23 SPSB4 0.3668 3.36xe-06 0.0494 0.0673 28 CPG island
cg09352908 5q12 PDE4D 0.4439 3.38xe-06 0.0494 0.0637 29 CGI-Shore
cg22078451 5q12 PDE4D 0.5968 3.53xe-06 0.0494 0.0641 30 CPG island
cg20916068 0.4586 3.58xe-06 0.0494 0.0986 31 Non-CGI
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umbilical cord blood and in utero arsenic exposure [8].
Even though previous studies have analysed DNA methy-
lation abnormalities in a larger population of smoker
mothers, they did not apply the Houseman correction,
as used in the present study.
DNA methylation patterns are essential for the growth
and maintenance of tissue-specific expression profiles in
different cell types during development, and these pat-
terns become set during in utero development [21,22].
This is true both in the fetus itself and in the placenta,
where changes to the appropriate methylation patterning
have been linked to adverse placental morphology andbirth outcomes [23,24]. A lower degree of placental global
DNA methylation in association with exposure to particu-
late air pollution during early pregnancy has been previ-
ously assessed [25], demonstrating how environmental
conditions affect gene specific DNA methylation and gene
expression patterns during the fetal period. Few human
studies have examined epigenetic alterations in relation
to maternal smoking during pregnancy [9-11]. These studies
have used a [3H]-methyl acceptance assay of global methyla-
tion [9], long interspersed nuclear element-1 (LINE-1) and
short interspersed element (AluYb8) [10], or differential
methylation at cytosine–guanine dinucleotide (CpG) sites
[11]. Maternal tobacco use during pregnancy has also been
Figure 2 Location of the 31 CpG sites differentially methylated
compared to all CpGs on the methylation array (all probes).
Methylation sites were categorized in groups according to their
location.
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specific methylation in human placenta [11] and buccal
cells from children [12]. Genes with a differing methyla-
tion pattern, reduced in the aryl hydrocarbon receptor re-
pressor gene (AHRR) and increased in the cytochrome
P450, family 1, subfamily A, polypeptide 1 (CYP1A1), have
been described in adult smokers [26] and in newborns ex-
posed to inutero tobacco [20]. DNA methylation is gen-
erally associated with gene transcription repression, and so
by consequence, a low level of methylation, usually in theFigure 3 Hierarchical clustering heat map including the CpG sites wit
non-exposed newborns.promoter region of the genes, allows for a higher expres-
sion of the encoded protein. On the other hand, high
methylation implies a lower expression. In the present
study, no different methylation pattern in these two genes
has been detected, possibly due to the sample size.
The results of the present study link the ADM hyper-
methylation to maternal smoking. This gene was identi-
fied in 1993 as a peptide with vasodilatation function,
but since then has been linked to a wide range of bio-
logical actions including cell growth, regulation of hormone
secretion and natriuresis [27]. Moreover, the ADM has been
found to be related to chronic diseases such as obesity and
comorbidities such as diabetes, atherosclerosis and coron-
ary heart disease [28,29], all of which have been associated
with in utero tobacco exposure [3]. This observation in-
creases the importance of the AHRR/ADM pathway as a
biomarker of early tobacco effects. Even though ADM was
not previously associated with maternal smoking and DNA
methylation, a recent study has demonstrated that ADM
significantly contributes to the carcinogenic effect of AHRR
and tobacco [30]. The study found that ADM and AHRR
were co-upregulated in lung tumour patients and the ADM
expression is dependent on tobacco exposure. Aryl hydro-
carbon receptor repressor gene directly regulates ADM
expression under normal physiologic conditions but may
also play a role during the early stages of tumour genesis
in the lung. Moreover, ADM is also a key peptide in car-
diovascular regulation [27-29]. Even though the long-termh significant differential methylation between exposed and
Ivorra et al. Journal of Translational Medicine  (2015) 13:25 Page 8 of 9significance of the ADM alteration observed in the present
study is unknown, the relationship between tobacco ex-
posure and elevated blood pressure, type 2 diabetes, and
obesity has been previously demonstrated [3].
Other loci were identified with higher or lower methy-
lation when compared between the exposed and non-
exposed groups. These can mediate their effects by: a)
regulation of gene transcription directly or indirectly
(FOXP4, ZNF827, AIRE, NAV2, POU2F, ZBTB45, PPP1R15,
ANKIRIN1, PLD3, RSU1 PDE4D); and b) protein synthesis
and processing (RPS2, RPL27, SPSB4, CLEF6, RPS25 and
RPL27). The potential impact of changes found in DNA
methylation can modify gene expression in a small propor-
tion, but these changes along life can result in important ef-
fects. Prospective studies of children exposed to tobacco in
which the DNA methylation pattern has been assessed can
help to clarify the impact of these alterations on the long
life effect.
Conclusions
In utero tobacco exposure, even in the absence of fetal
growth restriction, may alter the epigenome, with global
DNA hypomethylation. Specific genes targeted by tobacco
exposure can be identified. The genes found indicate that
the potential cellular mechanisms modified by tobacco ex-
posure are numerous and involve different overall regula-
tion mechanisms. The DNA status at birth can therefore
be used as a biomarker of prenatal insults. While studies
of the cord blood give an indication of epigenetic changes
experienced in utero, the question remains if this in utero
exposure persists into childhood and adulthood. Consider-
ing the possibility to reverse epigenetic modifications, a
window of opportunity exists to modify the programmed
chronic disease. Prospective studies are necessary to assess
the impact of epigenomic changes at birth, on health and
disease.
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